{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:24:37Z","timestamp":1794270277917,"version":"4.9.0"},"reference-count":260,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.arr.2026.103263","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:26:46Z","timestamp":1784302006000},"page":"103263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting neuroinflammation and neurodegeneration in Parkinson\u2019s disease: Emerging natural and synthetic therapeutic strategies"],"prefix":"10.1016","volume":"121","author":[{"given":"Safia","family":"Arbab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanif","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease\u2014epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2026.103263_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2026.103263_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105357","article-title":"Levodopa, homocysteine and Parkinson's disease: What's the problem?","volume":"109","author":"Ahlskog","year":"2023","journal-title":"Park. & Relat. Disord."},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00210-022-02258-8","article-title":"Scutellaria baicalensis and its constituents baicalin and baicalein as antidotes or protective agents against chemical toxicities: A comprehensive review","volume":"395","author":"Ahmadi","year":"2022","journal-title":"Naunyn-Schmiede 's. Arch. Pharmacol."},{"key":"10.1016\/j.arr.2026.103263_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115408","article-title":"Targeted protein degradation for the treatment of Parkinson\u2019s disease: Advances and future perspective","volume":"166","author":"Amirian","year":"2023","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.arr.2026.103263_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101515","article-title":"REM sleep behavior disorder: Mimics and variants","volume":"60","author":"Antelmi","year":"2021","journal-title":"Sleep. Med. Rev."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41573-024-01105-0","article-title":"Targeting mitophagy in neurodegenerative diseases","volume":"24","author":"Antico","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1444-0938.2012.00770.x","article-title":"Visual signs and symptoms of dementia with Lewy bodies","volume":"95","author":"Armstrong","year":"2012","journal-title":"Clin. Exp. Optom."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jnnp-2012-303135","article-title":"Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology","volume":"84","author":"Asahina","year":"2013","journal-title":"J. Neurol. Neurosurg. & Psychiatry"},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib12","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.3390\/ijms22094676","article-title":"The contribution of microglia to neuroinflammation in Parkinson\u2019s disease","volume":"22","author":"Badanjak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib13","first-page":"20","article-title":"A review on herbal drugs used in parkinson\u2019s disease","author":"Badri","year":"2023","journal-title":"Int. J. Indig. Herbs Drugs"},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1212\/WNL.55.9.1358","article-title":"Parkinson\u2019s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men","volume":"55","author":"Baldereschi","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jcmm.17635","article-title":"Therapeutic properties and pharmacological activities of asiaticoside and madecassoside: A review","volume":"27","author":"Bandopadhyay","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib16","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1002\/ptr.7203","article-title":"Bacosides from Bacopa monnieri extract: An overview of the effects on neurological disorders","volume":"35","author":"Banerjee","year":"2021","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5483\/BMBRep.2022.55.1.162","article-title":"Stem cell-derived extracellular vesicle therapy for acute brain insults and neurodegenerative diseases","volume":"55","author":"Bang","year":"2022","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13205-025-04681-z","article-title":"Advances in therapeutic hybrid neuromodulation for Parkinson\u2019s disease","volume":"16","author":"Bano","year":"2026","journal-title":"3 Biotech"},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/glia.20015","article-title":"Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure","volume":"46","author":"Barcia","year":"2004","journal-title":"Glia"},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","article-title":"Cell-based therapies for Parkinson disease\u2014past insights and future potential","volume":"11","author":"Barker","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib21","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","article-title":"Nanoparticles for drug delivery in Parkinson\u2019s disease","volume":"268","author":"Baskin","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep45883","article-title":"A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3\u2032 end using CRISPR-Cas9 genome editing technique","volume":"7","author":"Basu","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-017-0428-y","article-title":"Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-na\u00efve Parkinson\u2019s disease patients","volume":"9","author":"Bedarf","year":"2017","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/0115665232292246240426125504","article-title":"Advancements in CRISPR-Based therapies for genetic modulation in neurodegenerative disorders","volume":"25","author":"Bhushan","year":"2025","journal-title":"Curr. Gene Ther."},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib25","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acschemneuro.0c00196","article-title":"\u03b1-Synuclein regulates iron homeostasis via preventing parkin-mediated DMT1 ubiquitylation in Parkinson\u2019s disease models","volume":"11","author":"Bi","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2026.103263_bib26","first-page":"22563","article-title":"Align your latents: High-resolution video synthesis with latent diffusion models, Proceedings of","author":"Blattmann","year":"2023","journal-title":"IEEE\/CVF Conf. Comput. Vision. Pattern Recognit."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib27","first-page":"37","article-title":"Focus: The Aging Brain: Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood\u2013brain barrier. challenges and tricks for CNS drug delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Sci. Pharm."},{"issue":"16","key":"10.1016\/j.arr.2026.103263_bib29","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3390\/cancers14164032","article-title":"Adenosine targeting as a new strategy to decrease glioblastoma aggressiveness","volume":"14","author":"Bova","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00401-014-1356-1","article-title":"Are cases with tau pathology occurring in the absence of A\u03b2 deposits part of the AD-related pathological process?","volume":"128","author":"Braak","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"8","key":"10.1016\/j.arr.2026.103263_bib31","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.26643","article-title":"Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis","volume":"31","author":"Broen","year":"2016","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib32","doi-asserted-by":"crossref","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","article-title":"Cell biology and pathophysiology of \u03b1-synuclein","volume":"8","author":"Burr\u00e9","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib33","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1038\/s41467-022-31787-2","article-title":"\u03b1-Synuclein fibril-specific nanobody reduces prion-like \u03b1-synuclein spreading in mice","volume":"13","author":"Butler","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2026.103263_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11910-012-0270-y","article-title":"Modeling Parkinson\u2019s disease using induced pluripotent stem cells","volume":"12","author":"Byers","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.20344\/amp.11978","article-title":"Doen\u00e7a de Parkinson: Revis\u00e3o cl\u00ednica e atualiza\u00e7\u00e3o [Parkinson's disease: Clinical review and update]","volume":"32","author":"Cabreira","year":"2019","journal-title":"Acta Med. Port."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell. death & Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41467-020-15109-y","article-title":"DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202215360","article-title":"\u03b1-Synuclein as a target for metallo-anti-neurodegenerative agents","volume":"62","author":"Cao","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.arr.2026.103263_bib39","first-page":"117","article-title":"Tea polyphenols in Parkinson\u2019s disease","author":"Caruana","year":"2015","journal-title":"Nat. Compd. Ther. Agents amyloidogenic Dis."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s004010050001","article-title":"Sequestration of iron by Lewy bodies in Parkinson\u2019s disease","volume":"100","author":"Castellani","year":"2000","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib41","article-title":"Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation","volume":"2","author":"Chamkouri","year":"2024","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.arr.2026.103263_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2026.103263_bib43","series-title":"Seminars in neurology","first-page":"399","article-title":"Disorders of sweating","author":"Cheshire","year":"2003"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169965","article-title":"Depletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial","volume":"12","author":"Ciesielska","year":"2017","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ijms20030725","article-title":"Targeting autophagy to overcome human diseases","volume":"20","author":"Condello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib47","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.arr.2026.103263_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112769","article-title":"Neurodegenerative diseases and Withania somnifera (L.): An update","volume":"256","author":"Dar","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib49","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.3390\/ijms24065945","article-title":"Canonical and non-canonical antipsychotics\u2019 dopamine-related mechanisms of present and next generation molecules: a systematic review on translational highlights for treatment response and treatment-resistant schizophrenia","volume":"24","author":"de Bartolomeis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.arr.2026.103263_bib50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/mds.25937","article-title":"The clinical spectrum of anxiety in Parkinson's disease","volume":"29","author":"Dissanayaka","year":"2014","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"cell"},{"key":"10.1016\/j.arr.2026.103263_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease","volume":"51","author":"Dolgacheva","year":"2019","journal-title":"J. Bioenerg. Biomembr."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","article-title":"Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions","volume":"8","author":"Dong-Chen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib54","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/brain\/aww006","article-title":"The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder","volume":"139","author":"Ehrminger","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103263_bib55","series-title":"Neuroimmune Pharmacology and Therapeutics","first-page":"671","article-title":"Therapeutic Strategies in Neurodegenerative Diseases","author":"Eid","year":"2024"},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00702-020-02167-1","article-title":"Parkinson\u2019s disease treatment: Past, present, and future","volume":"127","author":"Elsworth","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2026.103263_bib57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fnins.2018.00612","article-title":"Parkinson\u2019s disease: biomarkers, treatment, and risk factors","volume":"12","author":"Emamzadeh","year":"2018","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib58","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.celrep.2013.02.016","article-title":"Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain","volume":"3","author":"Emborg","year":"2013","journal-title":"Cell. Rep."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","article-title":"Safety and efficacy of continuous subcutaneous levodopa\u2013carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial","volume":"23","author":"Espay","year":"2024","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-024-12730-5","article-title":"Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology","volume":"272","author":"Fanciulli","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2026.103263_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol. & Ther."},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib62","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/brainsci11121588","article-title":"Neurophysiological aspects of REM sleep behavior disorder (RBD): a narrative review","volume":"11","author":"Figorilli","year":"2021","journal-title":"Brain Sci."},{"issue":"21","key":"10.1016\/j.arr.2026.103263_bib63","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.3390\/ijms252111658","article-title":"Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues","volume":"25","author":"Firdaus","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.2003.tb07469.x","article-title":"Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease","volume":"991","author":"Fiskum","year":"2003","journal-title":"Ann. New. Y. Acad. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10665","article-title":"Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders","author":"Flores-Fernandez","year":"2024","journal-title":"Bioeng. & Transl. Med."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1353-8020(99)00043-7","article-title":"MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?","volume":"6","author":"Foley","year":"2000","journal-title":"Park. & Relat. Disord."},{"issue":"18","key":"10.1016\/j.arr.2026.103263_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800311","article-title":"GPX4 at the crossroads of lipid homeostasis and ferroptosis","volume":"19","author":"Forcina","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.arr.2026.103263_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fpsyt.2018.00068","article-title":"Adenosine A2A receptor antagonists in neurodegenerative diseases: huge potential and huge challenges","volume":"9","author":"Franco","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib69","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/ncb3064","article-title":"Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice","volume":"16","author":"Friedmann Angeli","year":"2014","journal-title":"Nat. Cell. Biol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40478-021-01145-2","article-title":"Cell specific quantitative iron mapping on brain slices by immuno-\u00b5PIXE in healthy elderly and Parkinson\u2019s disease","volume":"9","author":"Friedrich","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"\u03b1-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell. Biol."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MLR.0000000000001840","article-title":"Analysis of the gene therapies authorized by the United States Food and Drug Administration and the European Medicines Agency","volume":"61","author":"Ghanem","year":"2023","journal-title":"Med. Care"},{"key":"10.1016\/j.arr.2026.103263_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2013.03.016","article-title":"Mesenchymal stem cells and neuroregeneration in Parkinson's disease","volume":"247","author":"Glavaski-Joksimovic","year":"2013","journal-title":"Exp. Neurol."},{"issue":"S2","key":"10.1016\/j.arr.2026.103263_bib74","first-page":"S81","article-title":"Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis","volume":"64","author":"Goetz","year":"2008","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc."},{"key":"10.1016\/j.arr.2026.103263_bib75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11481-014-9569-6","article-title":"Potential neuroprotective activity of Ginseng in Parkinson\u2019s disease: a review","volume":"10","author":"Gonz\u00e1lez-Burgos","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.arr.2026.103263_bib76","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1201\/9781315168258-22","article-title":"Magnetic nanoparticles for neural engineering","author":"Goya","year":"2018","journal-title":"Clin. Appl. Magn. Nanopart."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib77","article-title":"Gold nanoparticles in Parkinson\u2019s disease therapy: a focus on plant-based green synthesis","volume":"16","author":"Grancharova","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","article-title":"Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease","volume":"16","author":"Hallett","year":"2015","journal-title":"Cell. stem Cell."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. & Ther."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib80","article-title":"Mucuna pruriens treatment for parkinson disease: a systematic review of clinical trials","volume":"2025","author":"Hammoud","year":"2025","journal-title":"Park. \u2019S. Dis."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib81","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: Non-L-dopa\u2013responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.37349\/ent.2023.00048","article-title":"Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease","volume":"3","author":"Henriquez","year":"2023","journal-title":"Explor. Neuroprotective Ther."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib84","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11930-024-00396-z","article-title":"Sexual Dysfunction in Patients with Neurological Disease","volume":"16","author":"Hentzen","year":"2024","journal-title":"Curr. Sex. Health Rep."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib85","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13287-022-03050-4","article-title":"The potential use of mesenchymal stem cells and their exosomes in Parkinson\u2019s disease treatment","volume":"13","author":"Heris","year":"2022","journal-title":"Stem Cell. Res. & Ther."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib86","first-page":"28","article-title":"Dopamine agonists for early Parkinson disease","volume":"80","author":"Hitzeman","year":"2009","journal-title":"Am. Fam. Physician"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib87","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib88","article-title":"Modeling Parkinson\u2019s disease using induced pluripotent stem cells","volume":"2020","author":"Hu","year":"2020","journal-title":"Stem Cells Int."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib89","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114712","article-title":"Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease","volume":"13","author":"Hwu","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib90","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3390\/antiox11061199","article-title":"Multi-target effects of \u00df-caryophyllene and carnosic acid at the crossroads of mitochondrial dysfunction and neurodegeneration: from oxidative stress to microglia-mediated neuroinflammation","volume":"11","author":"Iorio","year":"2022","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib91","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(24)00170-4","article-title":"Sleep and sleep disorders in people with Parkinson's disease","volume":"23","author":"Iranzo","year":"2024","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib92","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1007\/s12035-021-02516-5","article-title":"Toxic feedback loop involving iron, reactive oxygen species, \u03b1-synuclein and neuromelanin in Parkinson\u2019s disease and intervention with turmeric","volume":"58","author":"Jansen van Rensburg","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2026.103263_bib94","series-title":"Inflammation in Parkinson's disease: scientific and clinical aspects","first-page":"25","article-title":"Neuropathology of Parkinson\u2019s disease","author":"Jellinger","year":"2014"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1212\/WNL.0000000000002876","article-title":"Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis","volume":"87","author":"Jellinger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103263_bib96","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J. Neural Transm."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib97","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","article-title":"A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease","volume":"129","author":"Jost","year":"2022","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2026.103263_bib98","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson\u2019s disease","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2026.103263_bib99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-12-381326-8.00009-0","article-title":"Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson\u2019s disease","volume":"95","author":"Kaakkola","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.22630","article-title":"Adenosine A2A receptor gene disruption protects in an \u03b1-synuclein model of Parkinson's disease","volume":"71","author":"Kachroo","year":"2012","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib101","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.arr.2026.103263_bib102","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/brainsci14080800","article-title":"Surgicogenomics: the role of genetics in deep brain stimulation in Parkinson\u2019s disease patients","volume":"14","author":"Kalinderi","year":"2024","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib103","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41589-019-0462-8","article-title":"Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death","volume":"16","author":"Kapralov","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00039.2017","article-title":"Induced pluripotent stem cells and their use in human models of disease and development","volume":"99","author":"Karagiannis","year":"2019","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10072-022-06356-6","article-title":"Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease","volume":"44","author":"Katta","year":"2023","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00207454.2018.1486837","article-title":"Awareness and current knowledge of Parkinson\u2019s disease: a neurodegenerative disorder","volume":"129","author":"Khan","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.arr.2026.103263_bib107","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib108","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00210-022-02229-z","article-title":"St. John\u02bcs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems? Naunyn-Schmiedeberg's","volume":"395","author":"Kholghi","year":"2022","journal-title":"Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib109","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","article-title":"Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease","volume":"13","author":"Kim","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"22","key":"10.1016\/j.arr.2026.103263_bib110","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.3390\/ijms252212369","article-title":"Gene Therapy for Parkinson\u2019s Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib111","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.3390\/ijms24108827","article-title":"Natural products as the potential to improve Alzheimer\u2019s and Parkinson\u2019s disease","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101618","article-title":"Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson\u2019s disease","volume":"78","author":"Kip","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib113","article-title":"Parkinson\u2032 s Disease and Mesenchymal Stem Cells: Potential for Cell-Based Therapy","volume":"2012","author":"Kitada","year":"2012","journal-title":"Park. \u2019S. Dis."},{"key":"10.1016\/j.arr.2026.103263_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.782082","article-title":"The gut\u2013brain axis and its relation to Parkinson\u2019s disease: a review","volume":"13","author":"Klann","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","article-title":"Pathogenesis of Parkinson disease\u2014the gut\u2013brain axis and environmental factors","volume":"11","author":"Klingelhoefer","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib116","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/01616412.2024.2301878","article-title":"Sleep quality, excessive daytime sleepiness, and depression in Parkinson\u2019s disease: implications for improved patient outcomes","volume":"46","author":"Kobak Tur","year":"2024","journal-title":"Neurol. Res."},{"issue":"15","key":"10.1016\/j.arr.2026.103263_bib117","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.3390\/app14156417","article-title":"Neuroprotective Benefits of Rosmarinus officinalis and Its Bioactives against Alzheimer\u2019s and Parkinson\u2019s Diseases","volume":"14","author":"Kosmopoulou","year":"2024","journal-title":"Appl. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib118","article-title":"Neuroprotective approaches to halt Parkinson's disease progression","volume":"158","author":"Krishnamurthy","year":"2022","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.arr.2026.103263_bib119","article-title":"A review of the botany, metabolites, pharmacology, toxicity, industrial applications, and processing of Polygalae Radix: the \u201ckey medicine for nourishing life","volume":"15","author":"Kuang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib120","article-title":"Medicinal Plants and Herbal Formulations Ameliorating Neurodegeneration: Remedies Combating Parkinson's and Alzheimer's Disease","volume":"15","author":"Kumar","year":"2023","journal-title":"J. Young-.-. Pharm."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib121","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1007\/s12602-024-10433-x","article-title":"Gut microbiota-based interventions for Parkinson\u2019s disease: neuroprotective mechanisms and current perspective","volume":"17","author":"Kumar","year":"2025","journal-title":"Probiotics Antimicrob. Proteins"},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib122","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.10167","article-title":"Sleep disorders in Parkinson's disease","volume":"17","author":"Kumar","year":"2002","journal-title":"Mov. Disord."},{"issue":"23","key":"10.1016\/j.arr.2026.103263_bib123","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/cells11233736","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib124","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.chest.2020.09.099","article-title":"The spectrum of sleep disorders in Parkinson disease: a review","volume":"159","author":"Lajoie","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.arr.2026.103263_bib125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12272-019-01133-0","article-title":"Significant roles of neuroinflammation in Parkinson\u2019s disease: therapeutic targets for PD prevention","volume":"42","author":"Lee","year":"2019","journal-title":"Arch. pharmacal Res."},{"key":"10.1016\/j.arr.2026.103263_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.141606","article-title":"Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson\u2019s disease by modulating \u03b1-synuclein aggregation and reactive oxygen species","volume":"461","author":"Lei","year":"2023","journal-title":"Chem. Eng. J."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib127","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12951-024-02587-1","article-title":"Microfluidics-enabled mesenchymal stem cell derived Neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson\u2019s Disease","volume":"22","author":"Lei","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib128","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.3390\/ijms24119721","article-title":"Inhibition of galectins and the P2X7 purinergic receptor as a therapeutic approach in the neurovascular inflammation of diabetic retinopathy","volume":"24","author":"Lepre","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2026.103263_bib130","article-title":"Emerging nanotechnology for treatment of Alzheimer\u2019s and Parkinson\u2019s disease","volume":"9","author":"Li","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.arr.2026.103263_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-9-47","article-title":"The role of the LRRK2 gene in Parkinsonism","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib132","first-page":"142","article-title":"A dual breakthrough in the treatment of Parkinson\u2019s disease: A narrative review of the mechanisms underlying deep brain stimulation electrode implantation and stem cell synergy","volume":"3","author":"Liang","year":"2026","journal-title":"Adv. Technol. Neurosci."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib133","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.arr.2026.103263_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101770","article-title":"Modulating SQSTM1\/p62-dependent selective autophagy of neurons by activating Nrf2 with multifunctional nanoparticles to eliminate \u03b1-synuclein aggregates and boost therapy of Parkinson\u2019s disease","volume":"49","author":"Liu","year":"2023","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib135","article-title":"Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson's disease by advanced nanoparticles","volume":"2","author":"Liu","year":"2023","journal-title":"MedCommBiomater. Appl."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib136","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/acsnano.9b06453","article-title":"A self-assembled \u03b1-synuclein nanoscavenger for Parkinson\u2019s disease","volume":"14","author":"Liu","year":"2020","journal-title":"ACS nano"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib137","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antiox12010012","article-title":"Baicalein attenuates brain iron accumulation through protecting aconitase 1 from oxidative stress in rotenone-induced Parkinson\u2019s disease in rats","volume":"12","author":"Liu","year":"2022","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.arr.2026.103263_bib138","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.3390\/ijms23084148","article-title":"Biomarker of neuroinflammation in Parkinson\u2019s disease","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-981-15-4272-5_2","article-title":"Autophagy and Parkinson\u2019s disease","author":"Lu","year":"2020","journal-title":"Autophagy biology diseases clinical science"},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045272","article-title":"Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway","volume":"7","author":"Luz-Crawford","year":"2012","journal-title":"PLoS. ONE"},{"issue":"15","key":"10.1016\/j.arr.2026.103263_bib141","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2174\/0113894501312703240826070530","article-title":"Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development","volume":"25","author":"Majumdar","year":"2024","journal-title":"Curr. Drug. Targets"},{"issue":"17","key":"10.1016\/j.arr.2026.103263_bib142","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.3390\/molecules25173926","article-title":"Neuroprotective properties of green tea (Camellia sinensis) in Parkinson\u2019s disease: A review","volume":"25","author":"Malar","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2026.103263_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102114","article-title":"Exploring parkinson-associated kinases for CRISPR\/cas9-based gene editing: beyond alpha-synuclein","author":"Mansour","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib144","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2174\/1389557519666191104110908","article-title":"Parkinson\u2019s disease: a review from pathophysiology to treatment","volume":"20","author":"Marino","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","article-title":"Parkinson's disease subtypes: lost in translation?","volume":"84","author":"Marras","year":"2013","journal-title":"J. Neurol. Neurosurg. & Psychiatry"},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib146","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.21586","article-title":"Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients","volume":"22","author":"Martinez-Martin","year":"2007","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib147","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1573407214666181026111431","article-title":"Valeriana spp.: biological activities and new in vitro and in vivo perspectives","volume":"16","author":"Martinho","year":"2020","journal-title":"Curr. Bioact. Compd."},{"key":"10.1016\/j.arr.2026.103263_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for Parkinson's disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib149","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","article-title":"Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities","volume":"93","author":"Menzies","year":"2017","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib150","first-page":"31","article-title":"A proposed roadmap for Parkinson\u2019s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein","volume":"9","author":"Merchant","year":"2019","journal-title":"J. Park. \u2019S. Dis."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib151","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/mds.27268","article-title":"Autonomic dysfunction in Parkinson's disease: a prospective cohort study","volume":"33","author":"Merola","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2026.103263_bib152","doi-asserted-by":"crossref","first-page":"s32","DOI":"10.1007\/s100720300035","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"24","author":"Micieli","year":"2003","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.arr.2026.103263_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121153","article-title":"Modulating autophagy and mitophagy as a promising therapeutic approach in neurodegenerative disorders","volume":"311","author":"Mishra","year":"2022","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.stemcr.2013.08.007","article-title":"Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate","volume":"1","author":"Morizane","year":"2013","journal-title":"Stem Cell. Rep."},{"issue":"13","key":"10.1016\/j.arr.2026.103263_bib156","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14656566.7.13.1715","article-title":"Levodopa, motor fluctuations and dyskinesia in Parkinson\u2019s disease","volume":"7","author":"Mueller","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.arr.2026.103263_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1792829","article-title":"Nanoengineered phytochemicals overcome blood\u2013brain barrier constraints in neurodegenerative disorders","volume":"17","author":"Naim","year":"2026","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib158","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/mds.29416","article-title":"Gene therapy for dopamine dyshomeostasis: from Parkinson's to primary neurotransmitter diseases","volume":"38","author":"Ng","year":"2023","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib159","first-page":"2117","article-title":"Role of NLRP3 inflammasome in Parkinson\u2019s disease and therapeutic considerations","volume":"12","author":"Nguyen","year":"2022","journal-title":"J. Park. 's. Dis."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib161","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Human. Mutat."},{"key":"10.1016\/j.arr.2026.103263_bib162","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease: an update","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.arr.2026.103263_bib163","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2013.02.012","article-title":"Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging","volume":"541","author":"Ohtsuka","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib164","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.3390\/ijms27125229","article-title":"Phytochemical Profile, Antioxidant Activity, and Neuroprotective Effects of Bacopa monnieri Extract in a Lipopolysaccharide-Induced Dementia Model","volume":"27","author":"Olajide","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103263_bib166","first-page":"1","article-title":"Medicinal Plants Against Neurological Viral Diseases: Ethnopharmacology, Chemistry, Clinical, and Preclinical Studies","author":"Pal","year":"2023"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib167","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.4103\/jdras.jdras_259_24","article-title":"Therapeutic potential of Glycyrrhiza glabra L. in managing oxidative stress-induced disorders","volume":"9","author":"Pandey","year":"2024","journal-title":"J. Drug. Res. Ayurvedic Sci."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib168","article-title":"An overview of Parkinson's disease: curcumin as a possible alternative treatment","volume":"14","author":"Patel","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib169","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1021\/acsbiomaterials.5c00004","article-title":"Advanced strategies in enhancing the hepatoprotective efficacy of natural products: integrating nanotechnology, genomics, and mechanistic insights","volume":"11","author":"Patel","year":"2025","journal-title":"ACS Biomater. Sci. & Eng."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13205-020-02253-x","article-title":"An assessment of potential nutritive and medicinal properties of Mucuna pruriens: a natural food legume","volume":"10","author":"Pathania","year":"2020","journal-title":"3 Biotech"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib171","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1358\/dot.2020.56.2.3098156","article-title":"Istradefylline: adenosine A2A receptor antagonist to reduce\" OFF\" time in Parkinson's disease","volume":"56","author":"Paton","year":"2020","journal-title":"Drugs Today (Barcelona Spain 1998)"},{"key":"10.1016\/j.arr.2026.103263_bib172","first-page":"973","article-title":"Innovative Biotechnology-Based Healthcare Products","author":"Patteti","year":"2026"},{"issue":"1-2","key":"10.1016\/j.arr.2026.103263_bib173","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neurol.2023.11.003","article-title":"An overview on pure autonomic failure","volume":"180","author":"Pavy-Le Traon","year":"2024","journal-title":"Rev. Neurol."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib174","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/biom12030371","article-title":"Epigallocatechin-3-Gallate (EGCG): New therapeutic perspectives for neuroprotection, aging, and neuroinflammation for the modern age","volume":"12","author":"Payne","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2026.103263_bib175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2021.05.026","article-title":"Mechanisms of antiparkinsonian anticholinergic therapy revisited","volume":"467","author":"Paz","year":"2021","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib176","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib177","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","article-title":"Role of TLR4 in the gut-brain axis in Parkinson\u2019s disease: a translational study from men to mice","volume":"68","author":"Perez-Pardo","year":"2019","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib178","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/biom11020306","article-title":"Epigenetics and communication mechanisms in microglia activation with a view on technological approaches","volume":"11","author":"Petralla","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2026.103263_bib179","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.csbj.2019.12.013","article-title":"The genomics of oxidative DNA damage, repair, and resulting mutagenesis","volume":"18","author":"Poetsch","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib181","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000276402","article-title":"Excessive daytime sleepiness in Parkinson\u2019s disease: characteristics and determinants","volume":"63","author":"Poryazova","year":"2010","journal-title":"Eur. Neurol."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib182","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib183","doi-asserted-by":"crossref","first-page":"24","DOI":"10.37349\/ent.2023.00036","article-title":"Pathophysiology of non-motor signs in Parkinsons disease: some recent updating with brief presentation","volume":"3","author":"Radad","year":"2023","journal-title":"Explor. Neuroprotective Ther."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib184","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimer's. & Dement."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib185","first-page":"1100","article-title":"Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders","volume":"23","author":"Rahbardar","year":"2020","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"10.1016\/j.arr.2026.103263_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.976385","article-title":"Multifunctional role of natural products for the treatment of Parkinson\u2019s disease: at a glance","volume":"13","author":"Rahman","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib187","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","article-title":"CRISPR-Cas9-based technology and its relevance to gene editing in Parkinson\u2019s disease","volume":"14","author":"Rahman","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib188","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","article-title":"Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders","volume":"14","author":"Raikwar","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib189","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00262-y","article-title":"A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy","volume":"6","author":"Rajakumar","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neurosci."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib191","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/pharmaceutics15061578","article-title":"Conjugation, prodrug, and co-administration strategies in support of nanotechnologies to improve the therapeutic efficacy of phytochemicals in the central nervous system","volume":"15","author":"Rassu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arr.2026.103263_bib192","series-title":"Oxidative stress and dietary antioxidants in neurological diseases","first-page":"249","article-title":"Antioxidant effects of Curcuma longa and its active constituent, curcumin, for the therapy of neurological disorders","author":"Razavi","year":"2020"},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib193","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00044-024-03203-5","article-title":"Motor and non-motor symptoms, drugs, and their mode of action in Parkinson\u2019s disease (PD): a review","volume":"33","author":"Saini","year":"2024","journal-title":"Med. Chem. Res."},{"issue":"1-2","key":"10.1016\/j.arr.2026.103263_bib194","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","article-title":"Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease","volume":"92","author":"Sakakibara","year":"2001","journal-title":"Auton. Neurosci."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.22519","article-title":"Genitourinary dysfunction in Parkinson's disease","volume":"25","author":"Sakakibara","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2026.103263_bib196","article-title":"Typology of sexual disorders in idiopathic Parkinson's disease, a systematic review","author":"Salardaine","year":"2024","journal-title":"Fr. J. Urol."},{"key":"10.1016\/j.arr.2026.103263_bib197","first-page":"389","article-title":"Levodopa","volume":"19","author":"Salat","year":"2013","journal-title":"Handb. Park. 's. Dis."},{"issue":"12","key":"10.1016\/j.arr.2026.103263_bib198","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400284","article-title":"AM404 Analogs as Activators of the 20S Isoform of the Human Proteasome","volume":"25","author":"Salazar-Chaparro","year":"2024","journal-title":"ChemBioChem"},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib199","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cger.2018.06.007","article-title":"Lewy body dementia","volume":"34","author":"Sanford","year":"2018","journal-title":"Clin. Geriatr. Med."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib200","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions","volume":"291","author":"Schapira","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.arr.2026.103263_bib201","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-1-4939-2089-1_45","article-title":"REM sleep behavior disorder","author":"Schenck","year":"2015","journal-title":"Sleep Medicine A Comprehensive Guide Development Clinical Milestones Advances Treatment"},{"key":"10.1016\/j.arr.2026.103263_bib202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10309-018-0226-6","article-title":"REM-Schlaf-Verhaltensst\u00f6rung: Bedeutung f\u00fcr Epileptologen","volume":"32","author":"Schenck","year":"2019","journal-title":"Z. F. \u00fcR. Epileptol."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib203","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/sleep\/25.2.120","article-title":"REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP","volume":"25","author":"Schenck","year":"2002","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib204","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.tips.2017.03.010","article-title":"Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP","volume":"38","author":"Schildknecht","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib205","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2026.103263_bib206","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.pbr.2019.10.006","article-title":"Innate and adaptive immune responses in Parkinson's disease","volume":"252","author":"Schonhoff","year":"2020","journal-title":"Progress. brain Res."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib207","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","article-title":"The synaptic pathology of \u03b1-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia","volume":"120","author":"Schulz-Schaeffer","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib208","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib209","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11064-023-04085-6","article-title":"The Role of IL-6 in Neurodegenerative Disorders","volume":"49","author":"Shan","year":"2024","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1515\/tnsci-2016-0016","article-title":"Enhancing attention in neurodegenerative diseases: Current therapies and future directions","volume":"7","author":"Sharma","year":"2016","journal-title":"Transl. Neurosci."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","article-title":"Non-recognition of depression and other non-motor symptoms in Parkinson's disease","volume":"8","author":"Shulman","year":"2002","journal-title":"Park. & Relat. Disord."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib213","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12640-019-00147-2","article-title":"NF-\u03baB-mediated neuroinflammation in Parkinson\u2019s disease and potential therapeutic effect of polyphenols","volume":"37","author":"Singh","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.arr.2026.103263_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.11.017","article-title":"NRF2 and NF-\u049bB interplay in cerebrovascular and neurodegenerative disorders: molecular mechanisms and possible therapeutic approaches","volume":"21","author":"Sivandzade","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.arr.2026.103263_bib215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neurobiolaging.2017.06.017","article-title":"Parkinsonian features in aging GFAP. HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment","volume":"58","author":"Song","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib216","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/acn3.51776","article-title":"LRRK2 and Parkinson's disease: from genetics to targeted therapy","volume":"10","author":"Sosero","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110166","article-title":"20S proteasome enhancers prevent cytotoxic tubulin polymerization-promoting protein induced \u03b1-synuclein aggregation","volume":"27","author":"Staerz","year":"2024","journal-title":"Iscience"},{"key":"10.1016\/j.arr.2026.103263_bib218","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"bmj"},{"key":"10.1016\/j.arr.2026.103263_bib219","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","article-title":"Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease","volume":"9","author":"Subramaniam","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13205-025-04674-y","article-title":"Advancing personalized medicine for Parkinson\u2019s disease: transforming treatment and therapeutic outcomes","volume":"16","author":"Swathi","year":"2026","journal-title":"3 Biotech"},{"key":"10.1016\/j.arr.2026.103263_bib221","article-title":"Dopamine boosts motivation for prosocial effort in Parkinson\u2019s disease","author":"Talbot","year":"2025","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib222","first-page":"477","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Park. 's. Dis."},{"issue":"20","key":"10.1016\/j.arr.2026.103263_bib223","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1042\/BCJ20160387","article-title":"Gsk3\u03b2 and Tomm20 are substrates of the SCFFbxo7\/PARK15 ubiquitin ligase associated with Parkinson's disease","volume":"473","author":"Teixeira","year":"2016","journal-title":"Biochem. J."},{"issue":"946","key":"10.1016\/j.arr.2026.103263_bib224","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/pgmj.2003.013912","article-title":"Long term motor complications of levodopa: clinical features, mechanisms, and management strategies","volume":"80","author":"Thanvi","year":"2004","journal-title":"Postgrad. Med. J."},{"issue":"3-2023","key":"10.1016\/j.arr.2026.103263_bib225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.51847\/cG1Zzxg06i","article-title":"Antioxidant activity of medicinal plant compounds and aminoacids for prevention of Alzheimer's disease","volume":"13","author":"Tsvetkova","year":"2023","journal-title":"J. Adv. Pharm. Educ. Res."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib226","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an \u03b1 synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Human. Vaccin. & Immunother."},{"key":"10.1016\/j.arr.2026.103263_bib227","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1225875","article-title":"The gut microbiota\u2013brain axis in neurological disorder","volume":"17","author":"Ullah","year":"2023","journal-title":"Front. Neurosci."},{"issue":"14","key":"10.1016\/j.arr.2026.103263_bib228","doi-asserted-by":"crossref","first-page":"10737","DOI":"10.1074\/jbc.M010907200","article-title":"Evidence for a partially folded intermediate in \u03b1-synuclein fibril formation","volume":"276","author":"Uversky","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib229","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"Van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-017-0778-2","article-title":"New therapeutic strategies for Lewy body dementias","volume":"17","author":"Velayudhan","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib231","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/01.wnl.0000266593.50534.e8","article-title":"Patient-reported autonomic symptoms in Parkinson disease","volume":"69","author":"Verbaan","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.arr.2026.103263_bib232","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/mds.20153","article-title":"Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT","volume":"19","author":"Visser","year":"2004","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib233","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10522-025-10320-0","article-title":"Enhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits","volume":"26","author":"Vittal","year":"2025","journal-title":"Biogerontology"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib234","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00702-023-02635-4","article-title":"The heterogeneity of Parkinson\u2019s disease","volume":"130","author":"W\u00fcllner","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2026.103263_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123014","article-title":"Treatment of Parkinson's disease model with human umbilical cord mesenchymal stem cell-derived exosomes loaded with BDNF","volume":"356","author":"Wang","year":"2024","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.arr.2026.103263_bib236","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10571-015-0161-2","article-title":"Ceruloplasmin is involved in the nigral iron accumulation of 6-OHDA-lesioned rats","volume":"35","author":"Wang","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.arr.2026.103263_bib237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-015-0042-0","article-title":"Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target","volume":"4","author":"Wang","year":"2015","journal-title":"Transl. Neurodegener."},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib238","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1021\/acs.nanolett.5b00964","article-title":"Monolayer PtSe2, a new semiconducting transition-metal-dichalcogenide, epitaxially grown by direct selenization of Pt","volume":"15","author":"Wang","year":"2015","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib239","article-title":"Curcumin-Activated Mesenchymal Stem Cells Derived from Human Umbilical Cord and Their Effects on MPTP-Mouse Model of Parkinson\u2019s Disease: A New Biological Therapy for Parkinson\u2019s Disease","volume":"2020","author":"Wang","year":"2020","journal-title":"Stem Cells Int."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.molmed.2022.02.003","article-title":"Ferroptosis in Parkinson\u2019s disease: glia\u2013neuron crosstalk","volume":"28","author":"Wang","year":"2022","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib241","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13607863.2022.2032601","article-title":"Systematic review of pharmacological interventions for people with Lewy body dementia","volume":"27","author":"Watts","year":"2023","journal-title":"Aging & Ment. Health"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib242","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.0b013e31825dcdc1","article-title":"Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes","volume":"79","author":"Weaver","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103263_bib243","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","article-title":"Pediatric cancer immunotherapy: opportunities and challenges","volume":"20","author":"Wedekind","year":"2018","journal-title":"Pediatr. Drugs"},{"issue":"6","key":"10.1016\/j.arr.2026.103263_bib244","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1474-4422(25)00125-5","article-title":"Gene therapy for Parkinson's disease: trials and technical advances","volume":"24","author":"Winston","year":"2025","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib245","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado4927","article-title":"A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson\u2019s disease","volume":"11","author":"Wu","year":"2025","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.arr.2026.103263_bib246","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202200192","article-title":"Tailoring a nanochaperone to regulate \u03b1-synuclein assembly","volume":"61","author":"Wu","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib247","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell. Res."},{"key":"10.1016\/j.arr.2026.103263_bib248","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1297408","article-title":"Advances in the regulatory mechanisms of mTOR in necroptosis","volume":"14","author":"Xie","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.arr.2026.103263_bib249","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1535682","article-title":"Recent advances in nanotechnology for Parkinson\u2019s disease: diagnosis, treatment, and future perspectives","volume":"12","author":"Yadav","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.arr.2026.103263_bib250","article-title":"The potential of natural products to inhibit abnormal aggregation of \u03b1-Synuclein in the treatment of Parkinson\u2019s disease","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib251","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1039\/C9FO02611H","article-title":"The effects of caloric restriction and its mimetics in Alzheimer's disease through autophagy pathways","volume":"11","author":"Yang","year":"2020","journal-title":"Food & Funct."},{"issue":"9","key":"10.1016\/j.arr.2026.103263_bib252","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1089\/ars.2009.2624","article-title":"Cell death pathways in Parkinson's disease: role of mitochondria","volume":"11","author":"Yao","year":"2009","journal-title":"Antioxid. & Redox Signal."},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib253","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9923331","article-title":"The positive role and mechanism of herbal medicine in Parkinson\u2019s disease","volume":"2021","author":"Yin","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.arr.2026.103263_bib254","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/toxins14040282","article-title":"Botulinum toxin therapy for oromandibular dystonia and other movement disorders in the stomatognathic system","volume":"14","author":"Yoshida","year":"2022","journal-title":"Toxins"},{"issue":"2","key":"10.1016\/j.arr.2026.103263_bib255","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpha.2020.06.002","article-title":"Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson\u2019s disease","volume":"11","author":"Yu","year":"2021","journal-title":"J. Pharm. Anal."},{"issue":"10","key":"10.1016\/j.arr.2026.103263_bib256","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","article-title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.arr.2026.103263_bib257","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10571-025-01556-y","article-title":"Herbal Interventions in Parkinson\u2019s Disease: A Systematic Review of Preclinical Studies","volume":"45","author":"Zhao","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.arr.2026.103263_bib258","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.arr.2026.103263_bib259","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14336\/AD.2019.0612","article-title":"Oxyphylla A promotes degradation of \u03b1-synuclein for neuroprotection via activation of immunoproteasome","volume":"11","author":"Zhou","year":"2019","journal-title":"Aging Dis."},{"issue":"8","key":"10.1016\/j.arr.2026.103263_bib260","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.7150\/thno.95953","article-title":"Stem cell-derived extracellular vesicles in the therapeutic intervention of Alzheimer's Disease, Parkinson's Disease, and stroke","volume":"14","author":"Zhou","year":"2024","journal-title":"Theranostics"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726002552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726002552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:11:19Z","timestamp":1794269479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163726002552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":260,"alternative-id":["S1568163726002552"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2026.103263","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting neuroinflammation and neurodegeneration in Parkinson\u2019s disease: Emerging natural and synthetic therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2026.103263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103263"}}